ArticleBMC nephrology2025
Histopathological spectrum and short-term outcome of rapidly progressive glomerulonephritis in children: a retrospective analysis from a tertiary care center.
Article in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRapidly progressive glomerulonephritis (RPGN) is a medical emergency in children. This study aims to determine histopathological spectrum and short-term outcome of RPGN due to membranoproliferative glomerulonephritis, lupus nephritis, infection-related glomerulonephritis, and ANCA-associated vasculitis.
methodsThis retrospective cohort study was conducted at the Sindh Institute of Urology and Transplantation and included children aged 1 to 18 years with RPGN. Diagnosis was based on kidney biopsy findings.The induction phase consisted of Steroids and Cyclophosphamide, followed by maintenance phase with either Azathioprine or Mycophenolate mofetil and low dose alternate day steroids. Outcome was assessed at 6, 12, 18 and 24 months.
resultsIn this study, 30 children were included with a mean age of 11 ± 2.5 years. Among these, 19 (63%) were females. The two most common etiologies were immune complex membranoproliferative glomerulonephritis(GN) 10 (33.3%) and pauci immune GN 10 (33.3%). At presentation, 8 (27%) required kidney support therapy for a median duration of 10 days (IQR 7–26). The eGFR and serum albumin significantly improved from baseline to 12 months (70.4 ± 62.6 versus 134.7 ± 58.5 ml/min/1.73 m2, p-value 0.00 and 2.5 ± 0.7 versus 3.8 ± 0.6 gm/dl, p-value 0.00). Mean follow up of all the participants was 29 ± 17 (12–48 months). At last follow-up complete remission, partial remission, chronic kidney disease and end stage kidney disease were observed in 16 (53%), 9 (30%), 3 (10%) and 2 (7%) respectively.
conclusionThe most common histopathological diagnoses were immune complex membranoproliferative GN and pauci-immune GN. Over one-fourth presented with severe kidney dysfunction requiring kidney support therapy. All patients received induction therapy with steroids and cyclophosphamide, followed by maintenance with azathioprine or mycophenolate mofetil plus low-dose alternate-day steroids. Complete remission was achieved in half of the children, while the remainder had partial remission or progressed to chronic or end-stage kidney disease. These findings underscore that early recognition and timely initiation of immunosuppressive therapy may improve short-term outcomes in crescentic glomerulonephritis. TRIAL REGISTER: Retrospective study design.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.